NRC FORM 313A (AUT) (07-31-2023)

U. S. NUCLEAR REGULATORY COMMISSION

APPROVED BY OMB: NO. 3150-0120

EXPIRES: 07/31/2026



Estimated burden per response to comply with this mandatory collection request: 4.3 hours. Submittal of the application is necessary to determine that the applicant is qualified and that adequate procedures exist to protect the public health and

*** Surres	AUTHORIZED USER TRAINING, EXPERIENCE, AND PRECEPTOR ATTESTATION (for uses defined under 35.300) [10 CFR 35.57, 35.390, 35.392, 35.394, and 35.396]	safety. Send comments regarding burden estimate to the FOIA, Library, and Information Collections Branch (T-6 A10M), U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, or by email to Infocollects.Resource@nrc.gov, and the OMB Reviewer at: OMB Office of Information and Regulatory Affairs, (3150-0120), Attn: Sofficer for the Nuclear Regulatory Commission, 725 17th Street NW, Washington, DC 20503; email:
------------	--	--

c. If currently authorized under 35.cclassroom and laboratory training, in sections 3.a., 3.b., and 3.c. may Attestation.	supervised work expe be used to document	erience, and super t this experience.	vised clinical cas	se experien	ce. The tab
Training and Experience forClassroom and Laboratory Train		d User 35.392	35.394	☐ 3 5	5.396
Description of Training	Location	on of Training		Clock lours	Dates of Training*
Radiation physics and instrumentation					
Radiation protection					
Mathematics pertaining to the use and measurement of radioactivity					
Chemistry of byproduct material for medical use					
Radiation biology					
	Total Hours of Train	ing:			
 Supervised Work Experience If more than one supervising individual Supervised Work 	<u> </u>		35.394 sing, provide multip	le copies of	396 this page.)
Description of Experience Must Include:		perience/License Imber of Facility	or Co	onfirm	Dates of Experience
Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation surveys				Yes No	
Performing quality control procedures on instruments used to determine the activity of dosages and performing checks for proper operation of survey meters				Yes No	
Calculating, measuring, and safely preparing patient or human research subject dosages				Yes No	
Using administrative controls to prevent a medical event nvolving the use of unsealed pyproduct material				Yes No	
Using procedures to contain spilled byproduct material safely and using proper decontamination procedures				Yes No	

	d Experience for Work Experience	Proposed Authorize (continued)	ed User (continued)			
Supervising Individual			License/Permit Number listing supervising individual as an authorized user			
Supervising ind		requirements below,	or equivalent Agreement State requirements			
☐ 35.390 ☐ 35.392 ☐ 35.394 ☐ 35.396 ☐ 35.57	With experience administering dosages of: Oral Nal-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries) Oral Nal-131 in quantities greater than 1.22 gigabecquerels (33 millicuries) Parenteral administration of any radioactive drug that contains a radionuclide that is primarily used for its electron emission, beta radiation characteristics, alpha radiation characteristics, or photon energy of less than 150 keV, for which a written directive is required.					
	** Supervising Authorized User must have experience in administering dosages in the same dosage category or categories as the individual requesting authorized user status.					
	Clinical Case Exp		ment supervised work experience, provide multiple	copies of		
Description of Experience Number of Cases Involving Personal Participation		Involving Personal	Location of Experience/License or Permit Number of Facility	Dates of Experience*		
Oral administration of sodium iodide I-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)						
Oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (33 millicuries)						
Parenteral administration of any radioactive drug that contains a radionuclide that is primarily used for its electron emission, beta radiation characteristics, alpha radiation characteristics, or photon energy of less than 150 keV, for which a written directive is required.						

(07-31-2023)

AUTHORIZED USER TRAINING, EXPERIENCE, AND PRECEPTOR ATTESTATION (for uses defined under 35.300) [10 CFR 35.57, 35.390, 35.392, 35.394, and 35.396] (continued)

3. Training	and Experience for Proposed Authorized	User (continued)			
c. Supervise	ed Clinical Case Experience (continued)				
Supervising Individual		License/Permit Number listing supervising individual as an authorized user			
Supervising in	ndividual meets the requirements below, or equiv	alent Agreement State requirements (check all that apply)**:			
35.390	35.390 ! With experience administering dosages of:				
35.392	Oral Nal-131 requiring a written directi gigabecquerels (33 millicuries)	Oral Nal-131 requiring a written directive in quantities less than or equal to 1.22			
35.394	Oral Nal-131 in quantities greater thar	n 1.22 gigabecquerels (33 millicuries)			
35.396 35.57	used for its electron emission, beta rad	Parenteral administration of any radioactive drug that contains a radionuclide that is primarily used for its electron emission, beta radiation characteristics, alpha radiation characteristics, or photon energy of less than 150 keV, for which a written directive is required.			
	** Supervising Authorized User must have experience in administering dosages in the same dosage category or categories as the individual requesting authorized user status.				
d. Provide c	completed Part II Preceptor Attestation.				
	PART II – PRECE	PTOR ATTESTATION			
lote: This part must be completed by the individual's preceptor. The preceptor does not have to be the supervising individual as long as the preceptor provides, directs, or verifies training and experience required. If more than one preceptor is necessary to document experience, obtain a separate preceptor statement from each.					
By che	ecking the boxes below, the preceptor is not	attesting to the individual's "general clinical competency."			
::					
First Section Check one of	the following for the requested authoriza	tion:			
For 35.390:					
☐ I attes	st that	has satisfactorily completed the 700 hours of training			
	Name of Proposed Authorized User	_			
and experience, including a minimum of 200 hours of classroom and laboratory training, as required by 10 CFR 35.390 (b)(1).					
For 35.392:					
☐ I attes	st that	has satisfactorily completed the 80 hours of classroom			
	Name of Proposed Authorized User	_			
and laboratory training, as required by 10 CFR 35.392(c)(1), and the supervised work and clinical case experience required in 35.392(c)(2).					
For 35.394:					
☐ Lattes	st that	has satisfactorily completed the 80 hours of classroom			
	Name of Proposed Authorized User	—			
	·	5.394 (c)(1), and the supervised work and clinical case			

Second Section							
I attest that	has satisfactorily completed the required clinical case						
	Name of Proposed Authorized User						
experience required in 35.390(b)(1)(ii)G listed below:							
	Oral Nal-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)						
Oral Nal-131	Oral Nal-131 in quantities greater than 1.22 gigabecquerels (33 millicuries)						
used for its el	ministration of any radioactive drug that contains a radionuclide that is primarily ectron emission, beta radiation characteristics, alpha radiation characteristics, or y of less than 150 keV, for which a written directive is required.						
Third Section							
☐ I attest that	is able to independently fulfill the radiation safety-related						
	Name of Proposed Authorized User						
duties as an auth	orized user for the medical uses authorized under 10 CFR 35.300 for:						
	requiring a written directive in quantities less than or equal to 1.22 ls (33 millicuries)						
Oral Nal-131	in quantities greater than 1.22 gigabecquerels (33 millicuries)						
photon energy Fourth Section For 35.396:	ectron emission, beta radiation characteristics, alpha radiation characteristics, or y of less than 150 keV, for which a written directive is required.						
I attest that	is an authorized user under 10 CFR 35.490 or 35.690						
	Name of Proposed Authorized User						
or equivalent Agreement State requirements, has satisfactorily completed the 80 hours of classroom and laboratory training, as required by 10 CFR 35.396 (b)(1), and the supervised work and clinical case experience required by 35.396(b)(2), and is able to independently fulfill the radiation safety-related duties as an authorized user under 10 CFR 35.300 for:							
Parenteral administration of any radioactive drug that contains a radionuclide that is primarily used for its electron emission, beta radiation characteristics, alpha radiation characteristics, or photon energy of less than 150 keV, for which a written directive is required.							
OR							
Board Certificati	on:						
☐ I attest that	has satisfactorily completed the board certification						
	Name of Proposed Authorized User						
training requi	of 35.396(a)(3), has satisfactorily completed the 80 hours of classroom and laboratory red by 10 CFR 35.396 (b)(1) and the supervised work and clinical case experience required by and is able to independently fulfill the radiation safety-related duties as an authorized user 8.35.300 for:						

Fifth Section					
Complete one of the following for the attestation and signature:					
Authorized User					
I meet the requirements below, or equivalent Agreement State r	equireme	ents, as an authorized user	r for:		
	; <u> </u>	35.57 for 35.300 uses			
I have experience administering dosages in the following categorequesting authorization:	ories for v	hich the proposed Author	ized User is		
Oral Nal-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)					
Oral Nal-131 in quantities greater than 1.22 gigabecquerels	(33 millio	uries)			
Parenteral administration of any radioactive drug that contains a radionuclide that is primarily used for its electron emission, beta radiation characteristics, alpha radiation characteristics, or photon energy of less than 150 keV, for which a written directive is required.					
OR					
Residency Program Director:					
I affirm that the attestation represents the consensus of the residency program faculty where at least one faculty member is an authorized user who meets the requirements below or equivalent Agreement State requirements:					
☐ 35.390 ☐ 35.392 ☐ 35.394 ☐ 35.39	96	35.57 for 35.300 uses			
I affirm that this facility member has experience in administering dosages in the same dosage category or categories for which the individual is requesting authorized user status and concurs with the attestation I am providing as program director.					
I affirm that the residency training program is approved by the:					
Residency Review Committee of the Accreditation Council for Graduate Medical Education					
Royal College of Physicians and Surgeons of Canada					
Council on Post-Graduate Training of the American Osteopathic Association					
I affirm that the residency training program includes training and experience specified in:					
☐ 35.390 ☐ 35.392 ☐ 35.394 ☐ 35.39	96				
Name of Facility:	License/F	Permit Number:			
Name of Preceptor or Residency Program Director (Typed or Printed)		Telephone Number	Date		
Signature					